Merck Newsroom WHITEHOUSE STATION, N.J., May 26, 2009 – GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck’s cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL is the first cervical cancer vaccine to receive WHO pre-qualification. WHO pre-qualification means that GARDASIL is now eligible for procurement by the United […]
Archives for November 2010
HPV shot dilemma: Should gay boys be targeted?
MSNBC.com If you thought the controversy over giving the HPV vaccine to girls was heated, just wait for the fight about the boys. A government health panel is expected to vote soon on whether to recommend vaccinating boys and young men against the human papillomavirus. Since 2006, the vaccine has been advised in girls and […]
Adverse reactions to cancer vaccine reported
Irish Times November 15, 2010 EITHNE DONNELLAN, Health Correspondent MORE THAN 60 adverse reactions to the cervical cancer vaccine used in the State’s national immunisation programme have been reported so far to the Irish Medicines Board (IMB). To date about 45,000 doses of the HPV vaccine have been given to school girls as part of […]
Update on National Monitoring Experience with Gardasil
IRISH MEDICINES BOARD 11th November 2010 The HSE human papillomavirus (HPV) Schools Immunisation Programme commenced in May 2010. It is estimated that 60,000 doses of Gardasil have been distributed and approximately 45,000 doses have been administered up to the end of October 2010. The Irish Medicines Board (IMB) has received a total of 64 reports […]
Influenza Vaccines for the Future
The New England Journal of Medicine Linda C. Lambert, Ph.D., and Anthony S. Fauci, M.D. N Engl J Med 2010; 363:2036-2044 November 18, 2010 Each year, seasonal epidemics of influenza cause serious illness and death throughout the world. In the United States, the annual burden of disease is estimated to be 25 million to 50 […]
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 18
- Next Page »